However, the percentages of IgM+ memory B cells were comparable between R and NonR NSCLC patients receiving anti-PD-L1 monotherapy (cohort 3 in Table 1, n = 30) (Figure 4E), which suggests the distinct role of IgM+ memory B cells in predicting the efficacy of anti-PD-1 and anti-PD-L1 therapies. The gene discussed is CD40LG; the disease is non-small cell lung carcinoma.